Massive claims study reveals Real-World SMA treatment patterns and costs

This study analyzed insurance claims from over 4,000 people with spinal muscular atrophy to see how three approved treatments (Zolgensma, Spinraza, and Evrysdi) are actually used in daily practice and what they cost over time. Researchers looked at dosing patterns, yearly drug costs, and overall healthcare expenses using data from 2016 to 2024. The goal was to understand real-world treatment habits and financial burden, not to test a new therapy.